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Introduction
The 93rd Annual Meeting of the American Association for
Cancer Research (AACR) was held in the vast under-
ground complex of the Moscone Convention Center in
downtown San Francisco, through mostly beautiful early
summer weather during 6–10 April 2002.
This diverse meeting, attended by more than 14,000
people, was dedicated to all methods of cancer research,
from basic cell biology to advanced clinical trials. The
meeting was presented in a multitude of formats: interac-
tive ‘meet the expert’ sessions (at 07:00 a.m.!), plenary
lectures, symposia, minisymposia, poster sessions, educa-
tional workshops, and panel discussions. Despite the
scope of the meeting, many of the presentations had an
intimate feel. This was in part because of the quantity and
quality of not-yet-published data that was presented, and
in part because of the atmosphere of discussion, even in
the largest lecture halls.
The present report will cover many of the topics that were
presented. Because of the scope of the conference,
however, the summaries that follow are only a representa-
tive sampling.
Molecular profiling: cDNA arrays and
proteomics
As evidenced by many talks at the conference, RNA tran-
script profiling technologies continue to mature, clearly
benefiting from the completion of the human genome
sequence. Kornelia Polyak (Dana-Farber Cancer Institute,
Harvard University, Boston, MA, USA) described serial
analysis of gene expression techniques used to identify
genes preferentially expressed in ductal carcinoma in situ.
Laura Van’t Veer (The Netherlands Cancer Institute,
Amsterdam, The Netherlands) performed a study in which
cDNA was prepared from affected tissue from breast
cancer patients, both before and after a 5-year treatment
period. Transcript analysis revealed a characteristic gene
expression pattern associated with intervening progres-
sion to metastasis. This pattern was used as a tool to eval-
uate a test group of patients and was found to have a
better predictive value than existing methods.
The sophistication and utility of proteomic analyses have
similarly grown. Several presentations came from the labo-
ratory of Emmanuel Petricoin (National Institutes of Health,
Bethesda, MD, USA), addressing the use of proteomics to
dissect the breast cancer phenotype in the context of
native cell–cell and cell–extracellular matrix interactions.
To improve signal strength and to reduce background,
human breast tumor cells were obtained by laser capture
microdissection of tumor tissue samples or from nipple
aspirate fluids, and were then subjected to western analy-
sis, protein microarray, and surface-enhanced laser des-
orption/ionization–time of flight mass spectrometry. These
techniques were used to compare normal breast epithe-
lium and invasive carcinomas, both before and after
therapy (e.g. Iressa inhibition of epidermal growth factor
[EGF]/ErbB1 signaling, or herceptin inhibition of
HER2/ErbB2 signaling). Similar work was presented by
Jinong Li (Johns Hopkins, Baltimore, MD, USA), who
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analyzed surface-enhanced laser desorption/ionization–
time of flight mass spectra of serum proteins to identify a
molecular signature of breast cancer.
A yet more sophisticated approach to proteomic analysis
was presented by Richard Caprioli (Vanderbilt University,
Nashville, TN, USA), in which the related technique of
matrix-assisted laser desorption/ionization–time of flight
mass spectrometry was used to scan the sample, creating
an image in which each pixel was composed of a com-
plete mass spectrum (from 2 to 100 kDa). Scanning
through the mass spectra revealed the distribution pat-
terns of proteins for any given molecular weight, and the
identity of the proteins could be pursued using mass
spectrometry–mass spectrometry techniques. Caprioli is
currently developing a microscopic laser with a resolution
of 2 µm to be used for imaging subcellular structures. The
tremendous size of his datasets points toward the great-
est current challenge in this field: the development of
more sophisticated computational tools to dissect key rel-
evant markers.
Nuclear structure, chromatin dynamics, and
genomic instability
In an early morning session, Stephen Doxsey (University of
Massachusetts Medical School, Boston, MA, USA) pre-
sented an excellent review of centrosome function and key
centrosome proteins, and gave a discussion of the role of
centrosome defects in the generation of genetic instability
and tumor progression. He also presented work from his
laboratory towards understanding these phenomena.
Joe W Gray (University of California, San Francisco, CA,
USA) presented a progression model that correlates the
number of gene abnormalities and overall genomic insta-
bility with the grade of malignancy in breast tumor (from
normal tissue, to hyperplastic lesions, to carcinoma in situ,
to invasive and metastatic tumors). William R Sellers
(Dana-Farber Cancer Institute, Boston, MA, USA) showed
that receptor tyrosine kinase genes are a particular target
of recurrent genomic aberrations during tumorigenic pro-
gression, an observation relevant to therapies targeting
those receptors or their signaling mediators.
The role of BRCA1 as a tumor suppressor acting in DNA
repair and the maintenance of genomic stability was
addressed in presentations by Stephen C West (Imperial
Cancer Research Fund, London, UK) and by David M
Livingston (Dana-Farber Cancer Institute, Boston, MA,
USA). The recently demonstrated interaction of BRCA1
with a variety of oncoproteins and tumor suppressors (e.g.
BRCA2, myc, p53, BARDI, etc.) was cited as evidence of
the complexity of BRCA1 signaling pathways. Results
were presented that BRCA1 acted to integrate signals
arising from the action of these other proteins. Further-
more, Livingston presented a hypothesis of why BRCA1
defects primarily manifest in women as breast cancer,
when he showed that BRCA1 could influence X-chromo-
some localization and inactivation.
Another alternative theory of breast cancer etiology was
presented by James F Holland (Mt Sinai School of Medi-
cine, New York, NY, USA), who proposed the existence of
a human-infectious form of the mouse mammary tumor
virus. Furthermore, he suggested that this virus could be
responsible for a substantial number of breast cancers,
such that the different distribution of mouse species
between Asian and non-Asian countries could account for
the different risks of breast cancer between Asian and
non-Asian women.
Targeting signaling pathways
The Dorothy P Landon/AACR prize for translational
research was given both to Elwood V Jensen (University of
Cincinnati, Cincinnati, OH, USA), who presented a histori-
cal synopsis of the identification of the estrogen receptor
(ER), and to V Craig Jordan (Northwestern University,
Chicago, IL, USA), who summarized the clinical potential
of anti-estrogens such as tamoxifen and raloxifene in the
treatment of breast cancer.
Continuing the theme of exploring the mechanistic basis of
signaling pathway inhibitors, Myles Brown (Dana-Farber
Cancer Institute, Harvard University, Boston, MA, USA) dis-
cussed how the tissue-specific effects of tamoxifen can be
dissected with chromatin immunoprecipitation experiments,
and how these results can point towards yet more efficient
chemoprevention strategies. This was followed by a presen-
tation from Carlos Arteaga (Vanderbilt University, Nashville,
TN, USA), speaking about successes with pathway
inhibitors such as herceptin, which inhibits HER2/ErbB2,
and Iressa, which inhibits EGF receptor/ErbB1, and how
these agents can have synergistic effects. A warning
against simplistic approaches with these inhibitors as
treatments for breast cancer was given by David F Stern
(Yale University School of Medicine, New Haven, CT,
USA), who discussed the complexity and heterogeneity in
mechanisms of HER2/ErbB2 activation and the fact that
different agonists can lead to completely different tran-
scriptional responses, such that herceptin may be an
effective treatment for a subset of, but not all,
HER2/ErbB2 overexpressing tumors. In relation to this,
Stern warned of the potential problem of using receptor
levels as a sole prognostic indicator, and suggested that
phosphorylation-specific antibodies to detect ErbB2 acti-
vation could be more reliable.
Leena A Hilakivi-Clarke (Georgetown University, Washing-
ton, DC, USA) spoke of her theory that the estrogen effect
in breast cancer occurs through the influence of estrogen
on a preinitiation step, rather than at initiation or progres-
sion. Namely, that estrogen acts as a carcinogen (or as a167
potentiator of carcinogenesis) during the fetal through
early developmental periods, but acts in suppressing
preinitiation events during puberty and pregnancy. Hilakivi-
Clarke hypothesized that this effect could be due to the
property of estrogen to upregulate expression and activity
of BRCA1. To apply this theory towards practical treat-
ments (since it is not reasonable to give estrogen supple-
ments to prepubescent girls), she has been experimenting
with dietary treatments that affect circulating estrogen
levels or activity, and assaying the results in the rat breast
cancer model.
Many general presentations contained many principles
that apply to breast cancer development and treatment.
Frank McCormick (University of California, San Francisco,
CA, USA) used his Memorial Award Lecture to provide an
overview of the role of phosphatidyl-3-kinase, Ras,
retinoblastoma, and p53 signal transduction pathways in
normal cellular function and in carcinogenesis, with an aim
towards developing integrative approaches that could
lead to new therapies. Daniel D Von Hoff (Arizona Cancer
Center, Tucson, AZ, USA) presented the results of a
series of new anticancer agents used in clinical trials
against breast and other cancers (full details are available
online: http://www.azcc.arizona.edu/VonHoff).
Various symposia examined growth factor receptors as
therapeutic targets, as well as how these strategies could
be combined with other treatments. Considering the ErbB
family, John Mendelson (University of Texas MD Anderson
Cancer Center, Houston, TX, USA) discussed the two
most promising new approaches: the use of function-
blocking monoclonal antibodies (such as herceptin), and
inhibitors of receptor tyrosine kinases (such as Iressa).
The discussion showed that either treatment can result in
inhibition of cell growth, in increased apoptosis, and in
potentiation of tumor responsiveness to conventional cyto-
toxic chemical and radiation therapies. J Shou (Baylor
College of Medicine, Houston, TX, USA) found that Iressa
blocks crosstalk between the ER and EGF, and thus cir-
cumvents the acquired resistance to tamoxifen in breast
cancer cells. R Bianco (Universita di Napoli ‘Federico II’,
Naples, Italy) determined that the antitumor effect of ioniz-
ing radiation was potentiated by Iressa in diverse cancer
cell lines. Santiago Ropero (Hospital 12 de Octubre,
Madrid, Spain) showed, however, that combination treat-
ment of breast cancer cells with herceptin and tamoxifen
could be additive, synergistic, or antagonistic for cell
growth, depending on concentrations and timing.
The advantages of the use of raloxifene over tamoxifen to
reduce breast cancer risk were presented by Powel Brown
(Baylor College of Medicine, Houston, TX, USA). Diverse
clinical trials have shown these to include reduced risk of
endometrial cancer. Brown also reviewed preclinical data
of new agents (retinoids and cyclooxygenase-2 inhibitors)
that prevent development of ER-negative and hormone-
independent breast tumors. Many posters were related to
the mechanisms involved in the development of ER-nega-
tive breast cancer. One such poster was by Jamie N Hol-
loway (Lombardi Cancer Center, Washington, DC, USA),
proposing that a substrate of MAP kinase is responsible
for ERα downregulation and progression to a hormone-
independent breast cancer. The poster by Yayun Liang
(Medical College of Georgia, Augusta, GA, USA)
described the antitumor effect of the antiprogestin mifepri-
stone towards inhibiting cellular growth and inducing apop-
tosis in ERα-negative human breast cancer cells through a
mechanism involving transforming growth factor beta 1.
Epigenetic contributions to breast cancer
development
Rudolf Jaenisch (The Whitehead Institute for Biomedical
Research, Cambridge, MA, USA) presented an overview
of the epigenome and some of his recent research. While
the best-characterized epigenetic mechanism involves
DNA methylation of gene promoter regions, Jaenisch used
colon and intestinal cancer models to show how additional
epigenetic agents as diverse as DNA methyl transferases,
histone deacetylases, histone acetyltransferases, tran-
scription factors, and chromatin remodeling machinery can
inhibit the expression of endogenous tumor suppressors.
Peter A Jones (USC/Norris Comprehensive Cancer
Center, Los Angeles, CA, USA) reviewed evidence that
aberrant methylation patterns are one of the most diagnos-
tic and earliest features in cell transformation, and pre-
sented his own work employing a methylation-sensitive
PCR technique to scan the genome in a bladder tumori-
genic cell line. He provided direct evidence that the exten-
sive de novo methylation of CpG islands in transformed
cell promoter regions can effectively ensure the silencing
of tumor suppressor genes. This was followed by a dis-
cussion of the practical uses of demethylating agents (5-
aza-2′-deoxycytidine, or zebularine) to restore cellular
growth control.
Thea Tlsty (University of California, San Francisco, CA,
USA) has found epigenetic downmodulation by hyper-
methylation of the p16INK4a promoter in cancerous and
precancerous lesions in many organs, including the
breast, as well as in histologically normal breast tissue
obtained by reduction mammoplasty. She showed that
mammary epithelial cells with a methylated p16 promoter
escape senescence, and that these cells pre-exist in vivo
and also can be derived in vitro, and can bypass normal
growth barriers by a cell intrinsic mechanism, in the
absence of any external carcinogen. Tlsty proposed that
these mammary epithelial cells could represent a breast
cancer precursor, and she is currently trying to identify
agents that selectively kill them while leaving normal
mammary epithelial cells intact.
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Integrative and complementary approaches
Ellen Warner (Toronto-Sunnybrook Cancer Center,
Toronto, Ontario, Canada) described a study testing mag-
netic resonance imaging (MRI) and ultrasound techniques
as additional/alternative methods for surveillance of
women at high risk for breast cancer. The use of these
techniques was prompted by the discomfort caused by
conventional mammography, by the propensity of such
cancers to develop in the dense breast tissue of younger
women, and by the concern that the ionizing radiation
associated with mammography could be deleterious for
individuals defective in DNA repair pathways involving
BRCA1 or BRCA2. MRI proved the most reliable method
for early detection, identifying 13 out of 18 tumors. On
combination of MRI with ultrasound and mammography,
17 of the 18 tumors were identified.
An excellent review of the current knowledge and chal-
lenges in the field of microenvironmental (cell–cell and
cell–extracellular matrix) control of cellular proliferation
was presented by Richard Assoian (University of Pennsyl-
vania, Pittsburgh, PA, USA) in a ‘meet the expert’ sunrise
session. The lively discussion far outlasted the scheduled
length of the seminar. William S Dalton (University of
Arizona, Tucson, AZ, USA), using a hematopoietic cell
model, demonstrated the contribution of the tumor
microenvironment on drug permeability and response, and
ultimate tumor treatment or resistance. Dalton suggested
that inhibition of cell adhesion or associated signaling
pathways could be used as a mechanism for increasing
the therapeutic effect of diverse chemotherapies.
Another new concept in drug resistance was presented by
Luisa Iruela-Arispe (University of California, Los Angeles,
CA, USA), who proposed that mammary tumors could be
inhibited, even in the presence of activating oncogenes,
by increasing the endogenous levels of anti-angiogenic
factors. Michael S O’Reilly (University of Texas MD Ander-
son Cancer Center, Houston, TX, USA), a forum modera-
tor of an angiogenesis symposium, presented the
advantages and limitations of the clinical use of anti-angio-
genic drugs in different types of cancer, concluding that
anti-angiogenic drugs are significantly effective in combi-
nation with other therapies.
The 2001–2002 AACR President, Waun Ki Hong (Univer-
sity of Texas MD Anderson Cancer Center, Houston, TX,
USA), presented an outstanding lecture concerning the
necessity of integrating biological markers from target
tissues with genetic susceptibility and epidemiologic
studies to establish strategies for early cancer detection
and chemoprevention. Hong proposed that cancer should
be considered as a chronic disease that follows a dynamic
process from initiation to progression, and he reviewed
the most promising therapeutic targets in diverse
cancers: inhibitors of growth factors, cyclooxygenase-2,
angiogenesis, signal transduction pathways, and activa-
tors of apoptosis and differentiation.
A poster presented by Thorarinn Gudjonsson (The Panum
Institute, Copenhagen, Denmark) described the isolation
and immortalization of a human breast epithelial cell popu-
lation with stem-like properties. These cells differentiate
into myoepithelial and luminal epithelial-type cells on
culture dishes, while they develop into gland-like struc-
tures with ducts and branching lobules when grown in
three-dimensional matrices. While much more validation
will be needed, the potential implications of this work to
advance our understanding of the genesis of breast
cancer were astounding.
Finally, in a very exciting ending for this intense meeting,
Malcolm Brenner (Baylor College of Medicine, Houston,
TX, USA) chaired one of the final symposia, concerning
new therapeutic approaches using current advances in
gene therapy. Many strategies were reviewed, including
the design of specific molecular antibodies, the introduc-
tion of an oncolytic virus or specific vectors to correct
tumor genetic defects, and genetic techniques to increase
host resistance and/or tumor sensitivity to treatment.
Similar techniques may ultimately lead to increased effective-
ness of endogenous antitumor immune responses.
Conclusion
The 93rd Annual Meeting of the AACR presented a wealth
of data and ideas, and provided opportunities for interac-
tion with the full spectrum of cancer researchers, from
basic scientists to active clinicians. The primary frustration
of the conference was the impossibility of attending every
promising talk; even working together, we were unable to
cover as much as we would have preferred. However, and
perhaps because of this, conference abstracts and a
number of the presentations are available online at the
AACR web page (www.aacr.org). Furthermore, stories of
general highlights are available to BioMedNet members
(news.bmn.com/conferences).
The 94th Annual AACR conference will be held in
Toronto, Ontario, Canada, 5–9 April 2003.
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